Novel Tool Enables High-Precision, Low-Cost Pediatric Leukemia Diagnostics

Researchers have introduced a novel diagnostics method that can more sensitively detect gene fusions in B-cell acute lymphoblastic leukemia (B-ALL), the most common type of pediatric cancer, compared to other publicly available fusion detection algorithms. The tool, detailed in an article appearing in The Journal of Molecular Diagnostics, published by Elsevier, enables a higher diagnostic yield from low-coverage, low-cost sequencing.

Current treatment of B-ALL is classified according to risk levels depending on age, white blood cell count, response to therapy, central nervous system status, and genomic subtype. Pediatric B-ALL is primarily driven by chromosomal abnormalities or structural variants, which typically result in fusion oncogenes that cause cancer cells to grow and multiply. It is critical to diagnose B-ALL genomic subtypes for appropriate risk-stratified treatment.

The novel algorithm, called FUSILLI (FUSions In Leukemia for Long-read sequencing Investigator), has been developed to detect these fusion genes. It uses Oxford Nanopore Technologies’ (ONT) long-read sequencing, which looks at larger DNA and RNA fragments and is easier to implement across various resource contexts compared to short-read sequencing technology.

The researchers working on this new tool have previously demonstrated the use of nanopore RNA sequencing to classify B-ALL. Now, the sensitive and accurate method for detecting gene fusion subtypes presented in FUSILLI closes a critical gap in using these data for clinical fusion detection.

“Long-read sequencing, and nanopore sequencing specifically, represent a new era of sequencing compared to more conventional short-read sequencing approaches. It has been around for about a decade but is now becoming mature enough for clinical applications,“ notes senior investigator Jeremy R. Wang, PhD, Department of Genetics, Department of Pathology and Laboratory Medicine, and Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill.

“Compared to traditional short-read next-generation sequencing, nanopore sequencing has dramatically lower capital and consumables costs and much faster turnaround time, making it particularly advantageous in resource-limited diagnostic settings. Our research builds on this technology to show the potential of diagnosing genomic subtypes of pediatric cancers, which are traditionally resolved through several different expertise- and resource-intensive assays.”

The investigators took a supervised approach at what filtering parameters were needed to detect true B-ALL gene fusions as compared to results obtained from clinical testing. For gene fusion detection, there can be false positives that result from both technical and computational artifacts.

“From our experience, we’ve seen sequencing chimeras (artificial DNA sequences created during the sequencing process), producing long reads that resemble true gene fusions. These are rare events. With careful filtering and sufficient sequencing depth, we discriminate these from true B-ALL gene fusions supported by a minimum of two reads,” explains Dr. Wang.

The study further established a limit of detection, finding that approximately 10 million reads per sample are required to reliably detect B-ALL fusions using this approach.

Additionally, researchers compared results against other publicly available fusions callers (with default parameters) and demonstrated superior sensitivity without significant loss of specificity for clinically relevant fusion events. Also, because they limited the data to clinically relevant B-ALL gene fusions, the researchers achieved a much smaller search space and faster computation times.

While the primary leukemic-driving fusions are the dominant fusion detected in most cases, the team observed an unexpected number of suggestive secondary alterations in the cohorts’ data. “For instance, we see PAX5::ZCCHC7 in several cases, which is a known secondary alteration, but less is known about its clinical relevance. A better understanding of these lesser-known genomic events that are not well captured by existing diagnostic tools has the potential to further improve risk stratification and personalized medicine.”

Dr. Wang concludes, “With the development of FUSILLI, we show the potential of using a single low-cost sequencing assay for diagnosing gene fusion subtypes of B-ALL, with faster turnaround time. Modern genomic subtyping in pediatric B-ALL informs risk-stratification and targeted therapy, improving treatment response rate and reducing unnecessary treatment-related toxicity.”

Notes for editors

The article is “Long-Read Whole-Transcriptome Sequencing and Selective Gene Panel Profiling Enable Sensitive Detection of Fusion Oncogenes in Pediatric B-Cell Acute Lymphoblastic Leukemia,” by John Lin, Kofi B. Opoku, Mark R. Litzow, Elisabeth Paietta, Ching-Hon Pui, Sima Jeha, Kathryn G. Roberts, Charles G. Mullighan, Thomas B. Alexander, and Jeremy R. Wang (https://doi.org/10.1016/j.jmoldx.2026.01.007). The article appears in volume 28, issue 5 (May 2026) of The Journal of Molecular Diagnostics, published by Elsevier.

The article is openly available at https://www.jmdjournal.org/article/S1525-1578(26)00021-8/fulltext.

Full text of the article is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 406 1313 or [email protected] to request a PDF of the article or additional information. To reach the study’s authors contact Lindsey Reich, Communications Specialist, UNC School of Medicine/UNC Health, Department(s) of Orthopaedics and Pathology and Laboratory Medicine, at [email protected].

This study was supported by the National Cancer Institute of the NIH under award numbers R01CA293366, R21CA259926, U10CA180820, UG1CA232760, and UG1CA189859; and National Institute of General Medical Sciences predoctoral training grant T32GM135123. Institutional and biobanking support was provided by UNC Lineberger Comprehensive Cancer Center, the University Cancer Research Fund, Hyundai Hope on Wheels, and Reelin’ for Research.

About The Journal of Molecular Diagnostics

The Journal of Molecular Diagnostics, the official publication of the Association for Molecular Pathology, co-owned by the American Society for Investigative Pathology, and published by Elsevier, seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome review articles that contain: novel discoveries or clinicopathologic correlations, including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition. www.jmdjournal.org

About Elsevier

Elsevier is a global leader in advanced information and decision support. For over a century, we have been helping advance science and healthcare to advance human progress. We support academic and corporate research communities, doctors, nurses, future healthcare professionals and educators across 170 countries in their vital work. We do this by delivering mission-critical insights and innovative solutions that combine trusted, evidence-based scientific and medical content with cutting-edge AI technologies to help impact makers achieve better outcomes. We champion inclusion and sustainability by embedding these values into our products and culture, working with the communities that we serve. The Elsevier Foundation supports research and health partnerships around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information, visit www.elsevier.com and follow us on social media @ElsevierConnect.